<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiovasc Diabetol</journal-id><journal-title>Cardiovascular Diabetology</journal-title><issn pub-type="epub">1475-2840</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15574199</article-id><article-id pub-id-type="pmc">PMC538252</article-id><article-id pub-id-type="publisher-id">1475-2840-3-10</article-id><article-id pub-id-type="doi">10.1186/1475-2840-3-10</article-id><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group></article-categories><title-group><article-title>Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Tenenbaum</surname><given-names>Alexander</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>altenen@post.tau.ac.il</email></contrib><contrib id="A2" corresp="yes" contrib-type="author"><name><surname>Fisman</surname><given-names>Enrique Z</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>zfisman@post.tau.ac.il</email></contrib></contrib-group><aff id="I1"><label>1</label>Cardiac Rehabilitation Institute, the Chaim Sheba Medical Center, 52621 Tel-Hashomer, Ramat-Gan, Israel</aff><aff id="I2"><label>2</label>Sackler Faculty of Medicine, Tel-Aviv University, 69978 Ramat-Aviv, Tel-Aviv, Israel</aff><pub-date pub-type="collection"><year>2004</year></pub-date><pub-date pub-type="epub"><day>1</day><month>12</month><year>2004</year></pub-date><volume>3</volume><fpage>10</fpage><lpage>10</lpage><ext-link ext-link-type="uri" xlink:href="http://www.cardiab.com/content/3/1/10"/><history><date date-type="received"><day>1</day><month>12</month><year>2004</year></date><date date-type="accepted"><day>1</day><month>12</month><year>2004</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2004 Tenenbaum and Fisman; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2004</copyright-year><copyright-holder>Tenenbaum and Fisman; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Tenenbaum
               Alexander
               
               
               altenen@post.tau.ac.il
            </dc:author><dc:title>
            Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?
         </dc:title><dc:date>2004</dc:date><dcterms:bibliographicCitation>Cardiovascular Diabetology 3(1): 10-. (2004)</dcterms:bibliographicCitation><dc:identifier type="sici">1475-2840(2004)3:1&#x0003c;10&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1475-2840</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><p>Although less clinical intervention studies have been performed with fibrates than with statins, there are evidences indicating that fibrates may reduce risk of cardiovascular events. The potential clinical benefit of the fenofibrate will be specified by the ongoing Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, which rationale, methods and aims have been just published.</p><p>Controlled clinical trials show similar or even greater cardiovascular benefits from statins-based therapy in patient subgroups with diabetes compared with overall study populations. Therefore, statins are the drug of first choice for aggressive lipid lowering actions and reducing risk of coronary artery disease in these patients. However, current therapeutic use of statins as monotherapy is still leaving many patients with mixed atherogenic dyslipidemia at high risk for coronary events. A combination statin/fibrate therapy may be often necessary to control all lipid abnormalities in patients with metabolic syndrome and diabetes adequately, since fibrates provide additional important benefits, particularly on triglyceride and HDL-cholesterol levels. Thus, this combined therapy concentrates on all the components of the mixed dyslipidemia that often occurs in persons with diabetes or metabolic syndrome, and may be expected to reduce cardiovascular morbidity and mortality.</p><p>Safety concerns about some fibrates such as gemfibrozil may lead to exaggerate precautions regarding fibrate administration and therefore diminish the use of the seagents. However, other fibrates, such as bezafibrate and fenofibrate appear to be safer and better tolerated. We believe that a proper co-administration of statins and fibrates, selected on basis of their safety, could be more effective in achieving a comprehensive lipid control as compared with monotherapy.</p></abstract><kwd-group><kwd>Diabetes mellitus</kwd><kwd>Dyslipidemia</kwd><kwd>Fibrates</kwd><kwd>Metabolic syndrome</kwd><kwd>Statins</kwd></kwd-group></article-meta></front><body><sec><title/><p>Due to their beneficial effects on glucose and lipid metabolism, peroxisome proliferator activated receptors (PPAR's) alpha agonists (fibrates) are good potential candidates for reducing the risk of myocardial infarction (MI) in subjects with metabolic syndrome [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>]. Although less clinical intervention studies have been performed with fibrates than with statins, there are evidences indicating that fibrates may reduce risk of cardiovascular disease and particularly non-fatal MI [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B10">10</xref>]. Interestingly, reduction of cardiovascular disease with one of the fibric acid derivates &#x02013; gemfibrozil &#x02013; was more pronounced in patients displaying baseline characteristics very similar to metabolic syndrome definitions [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>].</p><p>There have been no direct head-to-head comparisons of a statin with a fibrate in any clinical endpoint trial. However, compared with statins, fibrates appear to more selectively target the therapeutic goals in obese individuals with features of insulin resistance and metabolic syndrome (i.e. with near-goal low-density lipoprotein (LDL)-cholesterol and inappropriate high-density lipoprotein (HDL)-cholesterol and triglyceride levels).</p><p>The primary-prevention trial Helsinki Heart Study showed that treatment with gemfibrozil led to a significant reduction in major cardiovascular events [<xref ref-type="bibr" rid="B4">4</xref>]. Regarding secondary prevention, in the VAHIT study (Veterans Affairs High-density lipoprotein cholesterol Intervention Trial) &#x02013; which included 30% of diabetic patients &#x02013; gemfibrozil reduced the occurrence of major cardiovascular events by 22 % [<xref ref-type="bibr" rid="B5">5</xref>]. Similarly, reduction of cardiovascular disease with gemfribrozil was more pronounced in patients displaying above three of the features of metabolic syndrome [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>].</p><p>In two previous small studies bezafibrate decreased the rate of progression of coronary atherosclerosis and decreased coronary event rate [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. In another large trial in 1568 men with lower extremity arterial disease with a relatively short follow-up period, bezafibrate reduced the severity of intermittent claudication for up to three years. [<xref ref-type="bibr" rid="B8">8</xref>]. Ingeneral, the incidence of coronary heart disease in patients on bezafibrate has tended to be lower , but this tendency did not reach statistical significance. However, bezafibrate had significantly reduced the incidence of non-fatal coronary events, particularly in those aged &#x0003c;65 years at entry, in whom all coronary events may also be reduced [<xref ref-type="bibr" rid="B8">8</xref>]. In the Bezafibrate Infarction Prevention (BIP) study an overall trend of a 9.4% reduction of the incidence of primary end point (fatal or non-fatal myocardial infarction or sudden death) was observed. The reduction in the primary end point in 459 patients with high baseline triglycerides (&#x02265;200 mg/dL) was significant [<xref ref-type="bibr" rid="B9">9</xref>]. These results are consistent with studies in experimental models showing that pre-treatment of rats with the PPAR-alpha agonist clofibrate causes a significant reduction in induced myocardial infarct size of 43% [<xref ref-type="bibr" rid="B13">13</xref>].</p><p>Recently, reduced incidence of type 2 diabetes in patients with impaired fasting glucose level on bezafibrate has been demonstrated [<xref ref-type="bibr" rid="B14">14</xref>]. The potential clinical benefit of the other widespread fibric acid derivative, fenofibrate, on the reduction of cardiovascular disease is still unknown and will be specified by the ongoing Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, which rationale, methods and aims have been just published [<xref ref-type="bibr" rid="B15">15</xref>]. It will be the largest (approximately 10000 patients) ever conducted fibrate-based controlled clinical trial in diabetic patients. The results are expected for 2005. An added strength of this trial is its ability to examine important clinical outcomes across diverse ethnic and gender subgroups. The results of this study will clarify whether the beneficial lipid-modifying effects of micronised fenofibrate lead to a reduction of cardiovascular morbidity and mortality.</p><p>Despite increasing use of statins, a significant number of coronary events still occur and many of such events take place in patients presenting with the metabolic syndrome. Whereas statins remain the drug of choice for patients who need to achieve the LDL-cholesterol goal, fibrate therapy may represent the alternative intervention for subjects with atherogenic dyslipidemia typical for metabolic syndrome and an LDL-cholesterol already close to goal values. In addition, the concomitant use of fibrates seems to be attractive in patients whose LDL-cholesterol is controlled by statin therapy but whose HDL-cholesterol and/or triglyceride levels are still inappropriate [<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B19">19</xref>]. This strategy will be tested in the ongoing Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial [<xref ref-type="bibr" rid="B20">20</xref>].</p><p>The factor that dominates in overweight-related metabolic syndrome is the permanent elevation of plasma free fatty acids (FFA) and the predominant utilization of lipids by the muscle inducing a diminution of glucose uptake and insulin resistance. Currently, an insulin-resistant state &#x02013; as the key phase of metabolic syndrome &#x02013; constitutes the major risk factor for development of macrovascular complications [<xref ref-type="bibr" rid="B21">21</xref>-<xref ref-type="bibr" rid="B23">23</xref>]. On the basis of the current concept of the evolution of adipogenesis via PPAR modulation toward insulin resistance and atherothrombotic macrovascular complications (including MI), the decreasing of plasma FFA and improving of insulin sensitization by PPAR agonists seems to be a logical and valuable goal for therapy.</p><p>It is important to note that on a whole-body level, lipid and glucose metabolisms interact intimately. Briefly, PPAR alpha is activated by fibric acids (e.g. bezafibrate) and form heterodimers with the 9-cis retinoic acid receptor (RXR). These heterodimers bind to peroxisome proliferator response elements, which are located in numerous gene promoters and increase the level of the expression of mRNAs encoded by PPAR alpha target genes. Bezafibrate reduces triglyceride plasma levels through increases in the expression of genes involved in fatty acid-beta oxidation and by decrease in apolipoprotein C-III gene expression. Fibric acids increase HDL-cholesterol partly by increasing apolipoprotein A-I and apolipoprotein A-II gene expression. Their triglyceride-lowering and HDL-cholesterol raising effects lead to decreased systemic availability of fatty acid, diminished fatty acid uptake by muscle with improvement of insulin sensitization and reduced plasma glucose level [<xref ref-type="bibr" rid="B24">24</xref>-<xref ref-type="bibr" rid="B28">28</xref>].</p><p>Evidence also suggests that there is a 'fibrate effect' that mediates the reduction in CHD risk beyond the favorable impact of these agents on HDL-cholesterol levels. This last notion is consistent with the pleiotropic effects of fibrates which are known to be related to their mechanisms of action [<xref ref-type="bibr" rid="B29">29</xref>]. Being PPAR alpha ligands, fibrates have a significant impact on the synthesis of several apolipoproteins (apo) and enzymes of lipoprotein metabolism as well as on the expression of several genes involved in fibrinolysis and inflammation. Such changes contribute to improve the catabolism of triglyceride-rich lipoproteins, leading to a substantial increase in HDL-cholesterol levels accompanied by a shift in the size and density of LDL particles (from small, dense LDL particles to larger, more buoyant cholesteryl ester-rich LDL).</p><p>Controlled clinical trials show similar or even greater cardiovascular benefits from statins-based therapy in patient subgroups with diabetes, impaired fasting glucose, and metabolic syndrome, compared with overall study populations. Therefore, statins are the drug of first choice for aggressive lipid lowering actions and reducing risk of coronary artery disease in these patients. However, current therapeutic use of statins as monotherapy is still leaving many patients with mixed atherogenic dyslipidemia at high risk for coronary events.</p><p>A combination statin/fibrate therapy may be often necessary to control all lipid abnormalities in patients with metabolic syndrome and diabetes adequately, since fibrates provide additional important benefits, particularly on triglyceride and HDL-C levels. Thus, this combined therapy concentrates on all the components of the mixed dyslipidemia that often occurs in persons with diabetes or metabolic syndrome, and may be expected to reduce cardiovascular morbidity and mortality.</p><p>Safety concerns about some fibrates such as gemfibrozil may lead to exaggerate precautions regarding fibrate administration and therefore diminish the use of the seagents. However, other fibrates such as bezafibrate and fenofibrate appear to be safer and better tolerated [<xref ref-type="bibr" rid="B30">30</xref>-<xref ref-type="bibr" rid="B36">36</xref>]. We believe that a proper co-administration of statins and fibrates, selected on basis of their safety, could be more effective in achieving a comprehensive lipid control as compared with monotherapy.</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work was supported in part by the Cardiovascular Diabetology Research Foundation (RA 58-040-684-1), Holon, Israel, and the Research Authority of Tel-Aviv University (Citernick grant 01250239).</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sacks</surname><given-names>FM</given-names></name><collab>for the Expert Group on HDL Cholesterol</collab></person-group><article-title>The role of high-density lipoprotein [HDL] cholesterol in the prevention and treatment of coronary heart disease: Expert Group recommendations</article-title><source>Am J Cardiol</source><year>2002</year><volume>90</volume><fpage>139</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">12106843</pub-id><pub-id pub-id-type="doi">10.1016/S0002-9149(02)02436-0</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fruchart</surname><given-names>JC</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism</article-title><source>Am J Cardiol</source><year>2001</year><volume>88</volume><fpage>24N</fpage><lpage>29N</lpage><pub-id pub-id-type="pmid">11788127</pub-id><pub-id pub-id-type="doi">10.1016/S0002-9149(01)02149-X</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Verges</surname><given-names>B</given-names></name></person-group><article-title>Clinical interest of PPARs ligands</article-title><source>Diabetes Metab</source><year>2004</year><volume>30</volume><fpage>7</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">15029092</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frick</surname><given-names>MH</given-names></name><name><surname>Elo</surname><given-names>O</given-names></name><name><surname>Haapa</surname><given-names>K</given-names></name><name><surname>Heinonen</surname><given-names>OP</given-names></name><name><surname>Heinsalmi</surname><given-names>P</given-names></name><name><surname>Helo</surname><given-names>P</given-names></name><name><surname>Huttunen</surname><given-names>JK</given-names></name><name><surname>Kaitaniemi</surname><given-names>P</given-names></name><name><surname>Koskinen</surname><given-names>P</given-names></name><name><surname>Manninen</surname><given-names>V</given-names></name></person-group><article-title>Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease</article-title><source>N Engl J Med</source><year>1987</year><volume>317</volume><fpage>1237</fpage><lpage>1245</lpage><pub-id pub-id-type="pmid">3313041</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rubins</surname><given-names>HB</given-names></name><name><surname>Robins</surname><given-names>SJ</given-names></name><name><surname>Collins</surname><given-names>D</given-names></name><name><surname>Fye</surname><given-names>CL</given-names></name><name><surname>Anderson</surname><given-names>JW</given-names></name><name><surname>Elam</surname><given-names>MB</given-names></name><name><surname>Faas</surname><given-names>FH</given-names></name><name><surname>Linares</surname><given-names>E</given-names></name><name><surname>Schaefer</surname><given-names>EJ</given-names></name><name><surname>Schectman</surname><given-names>G</given-names></name><name><surname>Wilt</surname><given-names>TJ</given-names></name><name><surname>Wittes</surname><given-names>J</given-names></name></person-group><article-title>Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group</article-title><source>N Engl J Med</source><year>1999</year><volume>341</volume><fpage>410</fpage><lpage>418</lpage><pub-id pub-id-type="pmid">10438259</pub-id><pub-id pub-id-type="doi">10.1056/NEJM199908053410604</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ericsson</surname><given-names>CG</given-names></name><name><surname>Nilsson</surname><given-names>J</given-names></name><name><surname>Grip</surname><given-names>L</given-names></name><name><surname>Svane</surname><given-names>B</given-names></name><name><surname>Hamsten</surname><given-names>A</given-names></name></person-group><article-title>Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT))</article-title><source>Am J Cardiol</source><year>1997</year><volume>80</volume><fpage>1125</fpage><lpage>1129</lpage><pub-id pub-id-type="pmid">9359536</pub-id><pub-id pub-id-type="doi">10.1016/S0002-9149(97)00626-7</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elkeles</surname><given-names>RS</given-names></name><name><surname>Diamond</surname><given-names>JR</given-names></name><name><surname>Poulter</surname><given-names>C</given-names></name><name><surname>Dhanjil</surname><given-names>S</given-names></name><name><surname>Nicolaides</surname><given-names>AN</given-names></name><name><surname>Mahmood</surname><given-names>S</given-names></name><name><surname>Richmond</surname><given-names>W</given-names></name><name><surname>Mather</surname><given-names>H</given-names></name><name><surname>Sharp</surname><given-names>P</given-names></name><name><surname>Feher</surname><given-names>MD</given-names></name></person-group><article-title>Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study</article-title><source>Diabetes Care</source><year>1998</year><volume>21</volume><fpage>641</fpage><lpage>648</lpage><pub-id pub-id-type="pmid">9571357</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meade</surname><given-names>T</given-names></name><name><surname>Zuhrie</surname><given-names>R</given-names></name><name><surname>Cook</surname><given-names>C</given-names></name><name><surname>Cooper</surname><given-names>J</given-names></name></person-group><article-title>Bezafibrate in men with lower extremity arterial disease: randomised controlled trial</article-title><source>BMJ</source><year>2002</year><volume>325</volume><fpage>1139</fpage><pub-id pub-id-type="pmid">12433762</pub-id><pub-id pub-id-type="doi">10.1136/bmj.325.7373.1139</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><article-title>Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study</article-title><source>Circulation</source><year>2000</year><volume>102</volume><fpage>21</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">10880410</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><collab>Diabetes Atherosclerosis Intervention Study Investigators</collab></person-group><article-title>Effect of fenofibrate on progression of coronary-artery disease in type 2diabetes: the diabetes atherosclerosis intervention study, a randomised study</article-title><source>Lancet</source><year>2001</year><volume>357</volume><fpage>905</fpage><lpage>910</lpage><pub-id pub-id-type="pmid">11289345</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(00)04209-4</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manninen</surname><given-names>V</given-names></name><name><surname>Tenkanen</surname><given-names>L</given-names></name><name><surname>Koskinen</surname><given-names>P</given-names></name><name><surname>Huttunen</surname><given-names>JK</given-names></name><name><surname>Manttari</surname><given-names>M</given-names></name><name><surname>Heinonen</surname><given-names>OP</given-names></name><name><surname>Frick</surname><given-names>MH</given-names></name></person-group><article-title>Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment</article-title><source>Circulation</source><year>1992</year><volume>85</volume><fpage>37</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">1728471</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rubins</surname><given-names>HB</given-names></name><name><surname>Robins</surname><given-names>SJ</given-names></name><name><surname>Collins</surname><given-names>D</given-names></name><name><surname>Nelson</surname><given-names>DB</given-names></name><name><surname>Elam</surname><given-names>MB</given-names></name><name><surname>Schaefer</surname><given-names>EJ</given-names></name><name><surname>Faas</surname><given-names>FH</given-names></name><name><surname>Anderson</surname><given-names>JW</given-names></name></person-group><article-title>Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT)</article-title><source>Arch Intern Med</source><year>2002</year><volume>162</volume><fpage>2597</fpage><lpage>2604</lpage><pub-id pub-id-type="pmid">12456232</pub-id><pub-id pub-id-type="doi">10.1001/archinte.162.22.2597</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wayman</surname><given-names>NS</given-names></name><name><surname>Ellis</surname><given-names>BL</given-names></name><name><surname>Thiemermann</surname><given-names>C</given-names></name></person-group><article-title>Ligands of the peroxisome proliferator-activated receptor-PPAR-a reduce myocardial infarct size</article-title><source>Med Sci Monit</source><year>2002</year><volume>8</volume><fpage>BR243</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">12118185</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tenenbaum</surname><given-names>A</given-names></name><name><surname>Motro</surname><given-names>M</given-names></name><name><surname>Fisman</surname><given-names>EZ</given-names></name><name><surname>Schwammenthal</surname><given-names>E</given-names></name><name><surname>Adler</surname><given-names>Y</given-names></name><name><surname>Goldenberg</surname><given-names>I</given-names></name><name><surname>Leor</surname><given-names>J</given-names></name><name><surname>Boyko</surname><given-names>V</given-names></name><name><surname>Mandelzweig</surname><given-names>L</given-names></name><name><surname>Behar</surname><given-names>S</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptors ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease</article-title><source>Circulation</source><year>2004</year><volume>109</volume><fpage>2197</fpage><lpage>2202</lpage><pub-id pub-id-type="pmid">15123532</pub-id><pub-id pub-id-type="doi">10.1161/01.CIR.0000126824.12785.B6</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keech</surname><given-names>AC</given-names></name><collab>the FIELD Study Investigators</collab></person-group><article-title>The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. ISRCTN64783481</article-title><source>Cardiovasc Diabetol</source><year>2004</year><volume>3</volume><fpage>9</fpage><pub-id pub-id-type="pmid">15571637</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robins</surname><given-names>SJ</given-names></name></person-group><article-title>Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?</article-title><source>Curr Opin Lipidol</source><year>2003</year><volume>14</volume><fpage>575</fpage><lpage>583</lpage><pub-id pub-id-type="pmid">14624134</pub-id><pub-id pub-id-type="doi">10.1097/00041433-200312000-00005</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fazio</surname><given-names>S</given-names></name><name><surname>Linton</surname><given-names>MF</given-names></name></person-group><article-title>The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy</article-title><source>Curr Atheroscler Rep</source><year>2004</year><volume>6</volume><fpage>148</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">15023300</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><article-title>Role of fibrates in reducing coronary risk: a UK Consensus</article-title><source>Curr Med Res Opin</source><year>2004</year><volume>20</volume><fpage>241</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">15006019</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tenenbaum</surname><given-names>A</given-names></name><name><surname>Fisman</surname><given-names>EZ</given-names></name><name><surname>Motro</surname><given-names>M</given-names></name></person-group><article-title>Bezafibrate and simvastatin: different beneficial effects for different therapeutic aims</article-title><source>J Clin Endocrinol Metab</source><year>2004</year><volume>89</volume><fpage>1978</fpage><pub-id pub-id-type="pmid">15070976</pub-id><pub-id pub-id-type="doi">10.1210/jc.2003-032038</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prisant</surname><given-names>LM</given-names></name></person-group><article-title>Clinical trials and lipid guidelines for type II diabetes</article-title><source>J Clin Pharmacol</source><year>2004</year><volume>44</volume><fpage>423</fpage><lpage>430</lpage><pub-id pub-id-type="pmid">15051751</pub-id><pub-id pub-id-type="doi">10.1177/0091270004263016</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Groop</surname><given-names>LC</given-names></name></person-group><article-title>Insulin resistance: the fundamental trigger of type 2 diabetes</article-title><source>Diabetes Obes Metab</source><year>1999</year><fpage>S1</fpage><lpage>S7</lpage><pub-id pub-id-type="pmid">11220283</pub-id><pub-id pub-id-type="doi">10.1046/j.1463-1326.1999.0010s1001.x</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tenenbaum</surname><given-names>A</given-names></name><name><surname>Fisman</surname><given-names>EZ</given-names></name><name><surname>Motro</surname><given-names>M</given-names></name></person-group><article-title>Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR)</article-title><source>Cardiovasc Diabetol</source><year>2003</year><volume>2</volume><fpage>4</fpage><pub-id pub-id-type="pmid">12834541</pub-id><pub-id pub-id-type="doi">10.1186/1475-2840-2-4</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lakka</surname><given-names>HM</given-names></name><name><surname>Laaksonen</surname><given-names>DE</given-names></name><name><surname>Lakka</surname><given-names>TA</given-names></name><name><surname>Niskanen</surname><given-names>LK</given-names></name><name><surname>Kumpusalo</surname><given-names>E</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name><name><surname>Salonen</surname><given-names>JT</given-names></name></person-group><article-title>The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men</article-title><source>JAMA</source><year>2002</year><volume>288</volume><fpage>2709</fpage><lpage>2716</lpage><pub-id pub-id-type="pmid">12460094</pub-id><pub-id pub-id-type="doi">10.1001/jama.288.21.2709</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fruchart</surname><given-names>JC</given-names></name><name><surname>Staels</surname><given-names>B</given-names></name><name><surname>Duriez</surname><given-names>P</given-names></name></person-group><article-title>The role of fibric acids in atherosclerosis</article-title><source>Curr Atheroscler Rep</source><year>2001</year><volume>3</volume><fpage>83</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">11123853</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rovellini</surname><given-names>A</given-names></name><name><surname>Sommariva</surname><given-names>D</given-names></name><name><surname>Branchi</surname><given-names>A</given-names></name><name><surname>Maraffi</surname><given-names>F</given-names></name><name><surname>Montalto</surname><given-names>C</given-names></name><name><surname>Gandini</surname><given-names>R</given-names></name><name><surname>Fasoli</surname><given-names>A</given-names></name></person-group><article-title>Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia</article-title><source>Pharmacol Res</source><year>1992</year><volume>25</volume><fpage>237</fpage><lpage>245</lpage><pub-id pub-id-type="pmid">1518767</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taniguchi</surname><given-names>A</given-names></name><name><surname>Fukushima</surname><given-names>M</given-names></name><name><surname>Sakai</surname><given-names>M</given-names></name><name><surname>Tokuyama</surname><given-names>K</given-names></name><name><surname>Nagata</surname><given-names>I</given-names></name><name><surname>Fukunaga</surname><given-names>A</given-names></name><name><surname>Kishimoto</surname><given-names>H</given-names></name><name><surname>Doi</surname><given-names>K</given-names></name><name><surname>Yamashita</surname><given-names>Y</given-names></name><name><surname>Matsuura</surname><given-names>T</given-names></name><name><surname>Kitatani</surname><given-names>N</given-names></name><name><surname>Okumura</surname><given-names>T</given-names></name><name><surname>Nagasaka</surname><given-names>S</given-names></name><name><surname>Nakaishi</surname><given-names>S</given-names></name><name><surname>Nakai</surname><given-names>Y</given-names></name></person-group><article-title>Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients</article-title><source>Metabolism</source><year>2001</year><volume>50</volume><fpage>477</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">11288046</pub-id><pub-id pub-id-type="doi">10.1053/meta.2001.21028</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jonkers</surname><given-names>IJ</given-names></name><name><surname>Mohrschladt</surname><given-names>MF</given-names></name><name><surname>Westendorp</surname><given-names>RG</given-names></name><name><surname>van der Laarse</surname><given-names>A</given-names></name><name><surname>Smelt</surname><given-names>AH</given-names></name></person-group><article-title>Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial</article-title><source>Am J Med</source><year>2002</year><volume>112</volume><fpage>275</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">11893366</pub-id><pub-id pub-id-type="doi">10.1016/S0002-9343(01)01123-8</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>IR</given-names></name><name><surname>Swai</surname><given-names>A</given-names></name><name><surname>Taylor</surname><given-names>R</given-names></name><name><surname>Miller</surname><given-names>M</given-names></name><name><surname>Laker</surname><given-names>MF</given-names></name><name><surname>Alberti</surname><given-names>KG</given-names></name></person-group><article-title>Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM</article-title><source>Diabetes Care</source><year>1990</year><volume>13</volume><fpage>855</fpage><lpage>863</lpage><pub-id pub-id-type="pmid">2209320</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Despres</surname><given-names>JP</given-names></name><name><surname>Lemieux</surname><given-names>I</given-names></name><name><surname>Robins</surname><given-names>SJ</given-names></name></person-group><article-title>Role of fibric Acid derivatives in the management of risk factors for coronary heart disease</article-title><source>Drugs</source><year>2004</year><volume>64</volume><fpage>2177</fpage><lpage>2198</lpage><pub-id pub-id-type="pmid">15456334</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jokubaitis</surname><given-names>LA</given-names></name></person-group><article-title>Fluvastatin in combination with other lipid-lowering agents</article-title><source>Br J Clin Pract Suppl</source><year>1996</year><volume>77A</volume><fpage>28</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">8729588</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gavish</surname><given-names>D</given-names></name><name><surname>Leibovitz</surname><given-names>E</given-names></name><name><surname>Shapira</surname><given-names>I</given-names></name><name><surname>Rubinstein</surname><given-names>A</given-names></name></person-group><article-title>Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety</article-title><source>J Intern Med</source><year>2000</year><volume>247</volume><fpage>563</fpage><lpage>569</lpage><pub-id pub-id-type="pmid">10809995</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2796.2000.00646.x</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kyrklund</surname><given-names>C</given-names></name><name><surname>Backman</surname><given-names>JT</given-names></name><name><surname>Kivisto</surname><given-names>KT</given-names></name><name><surname>Neuvonen</surname><given-names>M</given-names></name><name><surname>Laitila</surname><given-names>J</given-names></name><name><surname>Neuvonen</surname><given-names>PJ</given-names></name></person-group><article-title>Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate</article-title><source>Clin Pharmacol Ther</source><year>2001</year><volume>69</volume><fpage>340</fpage><lpage>345</lpage><pub-id pub-id-type="pmid">11372002</pub-id><pub-id pub-id-type="doi">10.1067/mcp.2001.115542</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beggs</surname><given-names>PW</given-names></name><name><surname>Clark</surname><given-names>DW</given-names></name><name><surname>Williams</surname><given-names>SM</given-names></name><name><surname>Coulter</surname><given-names>DM</given-names></name></person-group><article-title>A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP)</article-title><source>Br J Clin Pharmacol</source><year>1999</year><volume>47</volume><fpage>99</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">10073746</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2125.1999.00846.x</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Farnier</surname><given-names>M</given-names></name><name><surname>Salko</surname><given-names>T</given-names></name><name><surname>Isaacsohn</surname><given-names>JL</given-names></name><name><surname>Troendle</surname><given-names>AJ</given-names></name><name><surname>Dejager</surname><given-names>S</given-names></name><name><surname>Gonasun</surname><given-names>L</given-names></name></person-group><article-title>Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil)</article-title><source>Am J Cardiol</source><year>2003</year><volume>92</volume><fpage>794</fpage><lpage>797</lpage><pub-id pub-id-type="pmid">14516878</pub-id><pub-id pub-id-type="doi">10.1016/S0002-9149(03)00885-3</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Farnier</surname><given-names>M</given-names></name></person-group><article-title>Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks</article-title><source>Am J Cardiovasc Drugs</source><year>2003</year><volume>3</volume><fpage>169</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">14727929</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shek</surname><given-names>A</given-names></name><name><surname>Ferrill</surname><given-names>MJ</given-names></name></person-group><article-title>Statin-fibrate combination therapy</article-title><source>Ann Pharmacother</source><year>2001</year><volume>35</volume><fpage>908</fpage><lpage>917</lpage><pub-id pub-id-type="pmid">11485144</pub-id><pub-id pub-id-type="doi">10.1345/aph.10315</pub-id></citation></ref></ref-list></back></article>



